Pancreatic Cancer Research

ResearcherEast China Normal UniversityActive in the last 2 years

Zhengfang Yi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3592-9912; OpenAlex author ID A5089954368. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 10

  1. Targeting WFS1 overcomes KRAS G12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer. Co-author DOI 10.1038/s41698-026-01553-4↗
  2. Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. Co-author DOI 10.1021/acscentsci.3c01440↗
  3. Correction: Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Last author DOI 10.1038/s41388-024-03044-x↗
  4. Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-22-0997↗
  5. Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment. Co-author DOI 10.1021/acs.jmedchem.2c01554↗
  6. Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic cancer. Co-author DOI 10.4155/fmc-2022-0168↗
  7. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Last author DOI 10.1038/s41388-020-01626-z↗
  8. The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer. Co-author DOI 10.1111/bph.15435↗
  9. Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targetin… Co-author DOI 10.1021/acs.jmedchem.9b00059↗
  10. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor recep… Co-author DOI 10.1111/j.1349-7006.2010.01778.x↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mingyao Liu · 7 shared papers, 2011–2024 · strength 0.90
  2. Yihua Chen · 6 shared papers, 2011–2024 · strength 0.75
  3. Chen Huang · 4 shared papers, 2021–2024 · strength 0.66
  4. Peng He · 3 shared papers, 2022–2024 · strength 0.48
  5. Zhenliang Sun · 2 shared papers, 2023–2024 · strength 0.34
  6. Yixi Chen · 1 shared paper, 2026 · strength 0.30
  7. Mingyao Liu · 1 shared paper, 2026 · strength 0.30
  8. Yunqi Li · 2 shared papers, 2019–2022 · strength 0.24
  9. Haijun Gu · 1 shared paper, 2022 · strength 0.16
  10. Q. He · 1 shared paper, 2021 · strength 0.13
  11. Jin‐Ming Gao · 1 shared paper, 2021 · strength 0.13
  12. Xin Wang · 1 shared paper, 2019 · strength 0.08
  13. Lijun He · 1 shared paper, 2011 · strength 0.03
  14. Xiufeng Pang · 1 shared paper, 2011 · strength 0.03
  15. Jieqiong Wang · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.